Skip to main content

Bristol-Myers Squibb Company (BMY)

Stock NYSE

$59.17

-1.85 (-2.94%)

Delayed quote.

Price history

Daily close
BMY daily closing price, Nov 20, 2025 to Nov 19, 2026 Closed at $45.94 on Nov 20, 2025 and $58.34 on Nov 19, 2026, a change of +26.99%. Range $45.94 to $68.09.
Daily closes, Nov 20, 2025 to Nov 19, 2026 (251 trading days).
Start
$45.94
Latest close
$58.34
Period change
+26.99%
Period low
$45.94
Period high
$68.09

Key metrics

Market cap
$124.85B
Volume
4.06M
Average volume
11.29M
52-week range
$45.52 – $68.64
Beta
0.23
Last dividend
$2.52
EPS (TTM)
$4.52
P/E ratio
13.09
Revenue (TTM)
$50.03B
Net income (TTM)
$9.24B
Total assets
$88.77B
Total debt
$44.81B
Cash and equivalents
$9.57B

Key financials (trailing twelve months).

Company profile

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
CEO
Christopher Boerner
Employees
32,500
Headquarters
Princeton, NJ, US
IPO date
1972-06-01

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$48.20B$48.30B$45.01B
Gross profit$34.26B$34.33B$34.31B
Operating income$13.72B$5.89B$8.20B
EBITDA$15.23B$3.17B$19.37B
Net income$7.05B-$8.95B$8.03B
Diluted EPS$3.45-$4.41$3.86
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$10.21B$10.35B$11.46B
Total assets$90.04B$92.60B$95.16B
Total liabilities$71.53B$76.22B$65.67B
Total debt$47.14B$51.20B$41.46B
Shareholders’ equity$18.47B$16.34B$29.43B
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$14.16B$15.19B$13.86B
Capital expenditure-$1.31B-$1.25B-$1.21B
Free cash flow$12.85B$13.94B$12.65B

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$13.07B$12.97B$11.49B$12.50B$12.22B$12.27B
Gross profit$8.92B$9.25B$8.07B$8.41B$8.79B$8.90B
Operating income$2.84B$4.03B$3.37B$2.81B$3.64B$3.77B
EBITDA$2.94B$5.09B$4.25B$2.88B$4.61B$3.27B
Net income$2.16B$3.32B$2.68B$1.09B$2.20B$1.31B
Diluted EPS$1.05$1.62$1.31$0.53$1.08$0.64
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$9.57B$8.72B$9.57B$10.21B$15.73B$12.60B
Total assets$88.77B$87.63B$86.48B$90.04B$96.89B$94.68B
Total liabilities$65.37B$65.31B$66.37B$71.53B$78.29B$77.19B
Total debt$44.81B$43.12B$46.43B$47.14B$51.04B$50.93B
Shareholders’ equity$23.40B$22.32B$20.07B$18.47B$18.55B$17.43B
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$4.18B$3.39B$1.10B$1.97B$6.31B$3.92B
Capital expenditure-$344.00M-$305.00M-$347.00M-$370.00M-$320.00M-$361.00M
Free cash flow$3.84B$3.09B$757.00M$1.60B$5.99B$3.56B